Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aditxt Inc ADTX

Healthcare Biotechnology
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.


NDAQ:ADTX - Post by User

Aditxt Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(240)
•••
Post by whytestockson Nov 07, 2024 7:32pm
22 Views
Post# 36302204

Aditxt's Target Acquisition Appili Therapeutics Announces Re

Aditxt's Target Acquisition Appili Therapeutics Announces Re
NEWS: $ADTX Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of ShareholdersAditxt, Inc. (NASDAQ: ADTX) (&#x201C;Aditxt&#x201D; or the &#x201C;Company&#x201D;), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (&#x201C;A...ADTX - Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities